Selank drops vs Injectable AC-Selank: what to choose for calm and focus

A synthetic seven-amino acid peptide has changed the approach to anxiety management. Selank was developed at the Institute of Molecular Genetics RAS as an analog of tuftsin - a natural immunomodulator. They added a Pro-Gly-Pro sequence to the C-terminus of the molecule to slow enzymatic breakdown and prolong brain activity [1].

But the format of peptide delivery to the body determines the result. Drops or injections? This isn't a question of convenience. It's a question of how much active substance actually reaches the target.

Two formats of one peptide: what's common and what differs

Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular weight of approximately 751 daltons [33]. The compact structure allows it to penetrate nasal mucosa and reach the central nervous system.

Both forms contain the same molecule. The difference is how it's modified for stability and by which route it enters the body.

Nasal drops 0.15% are a pharmaceutical product approved in Russia in 2009 for treating generalized anxiety disorder [1]. A 0.15% concentration means 75 μg per drop. Standard protocol: 2-3 drops in each nostril three times daily for 10-14 days [12].

AC-Selank-NH2 is an acetylated and amidated version of the same peptide. Acetylation protects the N-terminus from carboxypeptidases, amidation protects the C-terminus [17]. Result: the molecule is more resistant to enzymatic breakdown.

Both forms modulate the GABAergic system without sedation and dependence, increase BDNF (brain-derived neurotrophic factor) expression, inhibit enkephalinase [1]. But the delivery route changes everything.

Pharmacy Selank: IMGen RAS nasal drops

The nasal form of Selank has existed for over 15 years. The Institute of Molecular Genetics created a 0.15% solution for intranasal administration [2]. In Russia, the drug is sold by prescription for treating anxiety-asthenic conditions.

How does nasal delivery work? Drops reach the nasal mucosa and are partially absorbed through olfactory pathways directly into the CNS. This bypasses the gastrointestinal tract where the peptide would be destroyed by proteases [5].

Nasal bioavailability of Selank is 30-40% [5]. The rest is lost through mucociliary clearance and local degradation.

Plasma half-life is 2-3 minutes [17]. But pharmacodynamic effects last much longer: anxiolytic action persists for several hours after a single dose, gene expression changes are recorded 1-24 hours after administration [17].

Practical nuance: drops should be directed at the nasal mucosa, not tilting the head back. Otherwise, the drug drains into the throat, causing unpleasant taste and reduced effectiveness [12].

The main disadvantage is dosing variability. Each drop may contain different amounts of active substance depending on bottle angle, pressure force, mucosal condition [7]. Studies with desmopressin showed: spray provides significantly higher AUC (area under the curve) and Cmax compared to drops [7].

AC-Selank-NH2: acetylated injectable form

AC-Selank-NH2 is a chemically modified version of the base molecule. An acetyl group at the N-terminus and an amide group at the C-terminus create double protection against enzymatic degradation [17].

Why is this important? Base Selank has a half-life of 2-3 minutes. Tuftsin, from which it derives - only 20-30 seconds [17]. Acetylation extends activity time by 5-10 times compared to the unprotected molecule.

Subcutaneous injection bypasses all first-pass barriers. Bioavailability reaches 95% - virtually the entire administered dose enters systemic circulation [30].

Research protocols use 250-500 μg per dose, 1-2 times daily [39]. This is significantly more precise compared to drops, where actual dose may differ by 30-50% from nominal.

Injectable form is particularly relevant for long-term protocols. Chronic use of nasal form may alter absorption characteristics through mucosal irritation [36]. Subcutaneous administration lacks this disadvantage.

Pen-injector format simplifies the procedure. The needle is thin, injection is virtually painless. Rotation of injection sites (abdomen, thigh) minimizes local irritation [15].

BBB penetration and bioavailability: comparing forms

The blood-brain barrier (BBB) is the main obstacle for neuroactive peptides. Selank has a compact 751-dalton molecule, theoretically facilitating penetration [33].

Nasal delivery has a unique advantage: part of the peptide penetrates through olfactory epithelium directly into the CNS, bypassing the BBB [5]. Studies with oxytocin confirm: intranasal administration provides higher local brain concentrations compared to systemic administration of the same dose [13].

But there's a caveat. These data were obtained for oxytocin, not Selank. Each peptide has unique penetration characteristics. Frontal cortex receives Selank after intranasal administration - this is confirmed by gene expression studies [21]. However, direct comparison of brain concentrations between nasal and injectable forms for Selank hasn't been conducted.

The figure 92.8% appears in some marketing materials [1], but most scientific sources indicate 30-40% for nasal bioavailability [5]. The higher figure likely refers to mucosal absorption rather than overall systemic bioavailability.

Subcutaneous injection provides predictable systemic delivery. The molecule enters bloodstream and distributes throughout the body, including the CNS. For AC-Selank-NH2, acetylation extends activity period, which may compensate for the less direct brain pathway.

Dosing precision: pen vs drops

When it comes to peptides, micrograms matter. Too little - no effect. Too much - side effects and cost waste.

Nasal drops demonstrate high dosing variability. Studies with PTH 1-34 (parathyroid hormone) showed: spray formulation provides significantly higher and more stable absorption compared to drops [4].

Table from desmopressin study illustrates the problem [7]:

Spray provided nearly three times higher AUC and Cmax. Drops drained into nasopharynx and were eliminated in 14-20 minutes, while spray remained on mucosa for 120-240 minutes.

Pen-injector solves the precision problem radically. Fixed volume, calibrated dose, reproducible result every time [11]. For research protocols this is critical: dosing variability destroys statistical validity.

For personal use, precision is also important. If you're trying to find your optimal dose, drop unpredictability complicates titration. Injectable form allows systematic dose selection with 50-100 μg steps.

When drops are sufficient and when injections are needed

Not every situation requires maximum bioavailability. Sometimes convenience matters more than optimization.

0.15% drops are suitable for:

• Mild to moderate anxiety
• Situational stress before events
• First attempts with the peptide (understand body response)
• Short-term 10-14 day courses
• Those who categorically refuse injections

Clinical studies with nasal Selank showed effectiveness in generalized anxiety disorder [27]. Patients noted improvement on days 4-5 of use [3]. For basic needs, nasal form works.

AC-Selank-NH2 (injections) chosen for:

• Severe anxiety unresponsive to drops
• Long-term protocols (over 3-4 weeks)
• Precise dosing for research purposes
• Combination with other peptides (e.g., Nootropics Booster)
• Maximizing bioavailability on limited budget

Cost is also a factor. Injectable form costs approximately the same, but with higher bioavailability you get more active substance per hryvnia. If counting the cost of actually absorbed peptide, injections are more economical.

Final choice depends on your goal, willingness for injections, and budget. Both forms work. The question is which works better specifically for you.

Where to order DOZA products

DOZA supplies all products mentioned in the article with official cold chain and 24/7 specialist support. Choose what you need:

• Buy Selank in Ukraine — anxiolytic peptide against stress eating, non-addictive.

FAQ